Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zenvia: Phase III start

This year, AVNR will start the double-blind, international Phase III STAR trial in about 270 patients with amyotrophic lateral sclerosis (ALS)

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE